CollPlant grants 510,372 RSUs to deputy CEO

CollPlant’s Deputy CEO and CFO received a large time‑vested RSU grant, bringing reported holdings to over 500,000 ordinary-share equivalents after a 1‑for‑10 reverse split.

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd (symbol: CLGN) is the issuer of record for a Form 4 filing submitted to the SEC. Rotem Eran reported acquisition or exercise transactions in this Form 4 filing.

CollPlant Biotechnologies Ltd (CLGN) reported that Deputy CEO and CFO Rotem Eran received a grant of 510,372 restricted share units (RSUs) on September 3, 2026, each RSU representing a contingent right to one ordinary share. 30% of these RSUs vest on September 3, 2027, and the remaining 70% vest in equal installments every three months over the following four years, with full vesting on September 3, 2031, subject to continued service. After this grant and giving effect to the issuer’s 1-for-10 reverse stock split effective September 4, 2026, Eran’s reported holdings total 516,372 ordinary-share equivalents, including newly awarded and previously held RSUs and shares.

Insider Trade Summary

Grant/Award: 510,372 shares

Grant/Award 1 txn

Insider Rotem Eran

Role Deputy CEO and CFO

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares F1, F2, F3	510,372	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 516,372 shares (Direct)

Footnotes (3)

1. F1. The Reporting Person was granted restricted share units ("RSUs"), each represents a contingent right to receive one ordinary share, no par value per share, of the Issuer ("Ordinary Shares"). The RSUs vest in accordance with the following vesting schedule: Thirty percent (30%) of the RSUs vest on September 3, 2027, and the remaining seventy percent (70%) vest in equal installments every three months thereafter over the following four years, such that the RSUs will be fully vested on September 3, 2031, subject to the Reporting Person's continued service to the Company through each vesting date.
2. F2. Effective as of September 4, 2026, the Issuer effected a 1-for-10 reverse stock split of its Ordinary Shares (the 'Reverse Stock Split'). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
3. F3. The total reported in Column 5 includes (i) 510,372 newly-awarded RSUs, (ii) 3,375 Ordinary Shares, and (iii) 2,625 previously-awarded RSUs.

Key Figures

RSUs granted: 510,372 RSUs Immediate vesting tranche: 30% of RSUs Remaining vesting period: 4 years +4 more

7 metrics

RSUs granted 510,372 RSUs Grant to Deputy CEO and CFO on September 3, 2026

Immediate vesting tranche 30% of RSUs Vests on September 3, 2027

Remaining vesting period 4 years 70% of RSUs vest quarterly over four years after initial vest

Total holdings after transaction 516,372 ordinary-share equivalents Column 5 total including RSUs and shares after grant and reverse split adjustment

Previously held RSUs 2,625 RSUs Included within the 516,372 total following the new grant

Ordinary shares held 3,375 shares Included within the 516,372 total following the new grant

Reverse stock split ratio 1-for-10 Effective September 4, 2026; amounts in the Form 4 adjusted accordingly

Key Terms

restricted share units ("RSUs"), Reverse Stock Split, vesting schedule

3 terms

restricted share units ("RSUs") financial

"The Reporting Person was granted restricted share units ("RSUs"), each represents"

Reverse Stock Split financial

"the Issuer effected a 1-for-10 reverse stock split of its Ordinary Shares (the 'Reverse Stock Split')"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

vesting schedule financial

"The RSUs vest in accordance with the following vesting schedule"

A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

FAQ

What equity award did CLGN grant to Deputy CEO and CFO Rotem Eran?

Rotem Eran was granted 510,372 restricted share units (RSUs) on September 3, 2026. Each RSU represents a contingent right to receive one CollPlant ordinary share, subject to the vesting schedule and continued service conditions described in the award.

How do the new RSUs for CLGN’s Deputy CEO and CFO vest over time?

30% of the RSUs vest on September 3, 2027. The remaining 70% vest in equal installments every three months over the next four years, so that all RSUs are fully vested on September 3, 2031, assuming continued service through each vesting date.

What are Rotem Eran’s total reported CLGN holdings after this Form 4 transaction?

Following the grant and after reflecting the reverse stock split, Rotem Eran’s Column 5 total is 516,372 ordinary-share equivalents, consisting of 510,372 newly awarded RSUs, 3,375 ordinary shares, and 2,625 previously awarded RSUs.

Did CollPlant (CLGN) effect a reverse stock split related to this Form 4?

Yes. Effective September 4, 2026, CollPlant effected a 1-for-10 reverse stock split of its ordinary shares. The share amounts reported in this Form 4 have been adjusted to reflect this reverse stock split.

Was the CLGN insider transaction reported under a Rule 10b5-1 trading plan?

No. The filing indicates that the Rule 10b5-1 checkbox is not marked as affirmative, and the footnotes do not state that the RSU grant was made pursuant to a Rule 10b5-1 trading plan.

What role does Rotem Eran hold at CollPlant Biotechnologies Ltd (CLGN)?

Rotem Eran is identified as Deputy CEO and Chief Financial Officer of CollPlant Biotechnologies Ltd, and is the reporting person receiving the RSU grant described in this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 04:06 PM Accepted by SEC EDGAR 09/08/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rotem Eran

(Last) (First) (Middle)

C/O COLLPLANT BIOTECHNOLOGIES LTD.

4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK

(Street)

REHOVOT 7670104

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
CollPlant Biotechnologies Ltd [ CLGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Deputy CEO and CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	09/03/2026		A		510,372(2)	A	$0	516,372(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted restricted share units ("RSUs"), each represents a contingent right to receive one ordinary share, no par value per share, of the Issuer ("Ordinary Shares"). The RSUs vest in accordance with the following vesting schedule: Thirty percent (30%) of the RSUs vest on September 3, 2027, and the remaining seventy percent (70%) vest in equal installments every three months thereafter over the following four years, such that the RSUs will be fully vested on September 3, 2031, subject to the Reporting Person's continued service to the Company through each vesting date.

2. Effective as of September 4, 2026, the Issuer effected a 1-for-10 reverse stock split of its Ordinary Shares (the 'Reverse Stock Split'). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

3. The total reported in Column 5 includes (i) 510,372 newly-awarded RSUs, (ii) 3,375 Ordinary Shares, and (iii) 2,625 previously-awarded RSUs.

	/s/ Eran Rotem	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)